Sonnet ditches biotech dreams to anchor a $583m HYPE token reserve
Sonnet BioTherapeutics is no longer just a cancer drug developer. Its $888 million merger will place it among the largest HYPE holders, blurring the lines between traditional finance and decentralized protocols in a high-stakes treasury experiment. According to a July 14 press release, Nasdaq-listed biotech firm Sonnet BioTherapeutics has agreed to an $888 million business … Read more